In other regulatory news:

The FDA released new draft guidance for the compounding industry in an effort to control purity and efficacy of the custom medications. Specifically, this new document provides a (non-exhaustive) list of “insanitary conditions” at compounding facilities that can be subject to forcible drug recalls. The draft is subject to a 60 day comment period.

Download the guidance here: FDA Draft Guidance for Compounders 8.3.16

Leave a Comment

Your email address will not be published. Required fields are marked *